ARTIVA BIOTHERAPEUTICS INC (ARTV) Stock News

USA - NASDAQ:ARTV - US04317A1079 - Common Stock

3.01 USD

+0.01 (+0.33%)

Last: 10/9/2025, 2:21:13 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ARTV Latest News, Press Relases and Analysis

All

Press Releases

20 days ago - By: Benzinga - Mentions: CCM APVO AQST SONN ...

12 Health Care Stocks Moving In Friday's Intraday Session

a month ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

a month ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

2 months ago - By: The Motley Fool

Artiva (ARTV) Q2 Loss Widens 19.7%

2 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

3 months ago - By: Benzinga - Mentions: CYH ABP APRE CASI ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

4 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

4 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

5 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

5 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

5 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

5 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

5 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

5 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

6 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

6 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

6 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

6 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

7 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

7 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

8 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

8 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

8 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

8 months ago - By: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.